Dopa-Responsive Dystonia

MONDO:0016812 Pathograph 12

Dopa-responsive dystonia (DRD) is a group of rare neurometabolic disorders in which inherited defects of dopamine biosynthesis cause childhood-onset dystonia that responds dramatically and durably to low-dose levodopa. Two genetic forms account for the majority of cases. Autosomal dominant DRD is most commonly due to heterozygous pathogenic variants in GCH1 (Segawa disease / GTPCH1-deficient DRD), with rarer dominant variants reported in IMPDH2 and NR4A2; it classically presents as childhood foot dystonia with diurnal fluctuation that may evolve into parkinsonism later in life. Autosomal recessive DRD is most commonly caused by biallelic TH (tyrosine hydroxylase) pathogenic variants, with rarer biallelic TSPOAP1 variants; its phenotype spans levodopa-responsive childhood dystonia, infantile parkinsonism with motor delay, and progressive infantile encephalopathy. Subtype-specific molecular detail is curated in the existing dismech entries `Autosomal_Dominant_Dopa_Responsive_Dystonia` and `Autosomal_Recessive_Dopa_Responsive_Dystonia`.

Ask OpenScientist

Ask a research question about Dopa-Responsive Dystonia. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

3
Pathophys.
6
Phenotypes
12
Pathograph
1
Treatments
2
Subtypes
2
References
1
Deep Research
◆

Subtypes

2
Autosomal Dominant Dopa-Responsive Dystonia
Most commonly due to heterozygous GCH1 pathogenic variants (Segawa disease / GTPCH1-deficient DRD); rarer dominant causes include IMPDH2 and NR4A2 variants. Curated as `Autosomal_Dominant_Dopa_Responsive_Dystonia`.
Autosomal Recessive Dopa-Responsive Dystonia
Most commonly due to biallelic TH (tyrosine hydroxylase) pathogenic variants; rarer biallelic TSPOAP1 variants also occur. Phenotypic spectrum from levodopa-responsive childhood dystonia to progressive infantile encephalopathy. Curated as `Autosomal_Recessive_Dopa_Responsive_Dystonia`.
⚙

Pathophysiology

3
Striatal Dopamine Biosynthesis Impairment
The unifying mechanism across DRD subtypes is reduced dopamine biosynthesis in nigrostriatal dopaminergic neurons, either via tetrahydrobiopterin-cofactor limitation (classically GCH1; see the `BH4 Cofactor Limitation` subtype-specific node) or via direct loss of tyrosine-hydroxylase activity (TH). The reversible neurotransmitter deficit at this shared endpoint accounts for the dramatic sustained response to low-dose levodopa that defines the disease group.
dopaminergic neuron link
dopamine biosynthetic process link ↓ DECREASED dopamine biosynthetic process from tyrosine link ↓ DECREASED catecholamine biosynthetic process link ↓ DECREASED
Downstream
Limb Dystonia Reduced nigrostriatal dopamine synthesis produces the childhood foot and limb dystonia that defines the DRD motor presentation.
Focal Dystonia The same central dopamine-synthesis deficit can present as focal dystonia, especially in the classic autosomal dominant subtype.
Parkinsonism Dopamine deficiency in motor circuits explains parkinsonian features in older classic DRD and in severe TH-deficient disease.
Gait Disturbance Foot and limb dystonia from the dopamine-synthesis deficit produces the characteristic childhood gait disturbance.
Decreased CSF Homovanillic Acid Homovanillic acid is a dopamine metabolite, so impaired central dopamine synthesis is reflected by low CSF homovanillic acid.
Show evidence (2 references)
PMID:28087438 SUPPORT Human Clinical
"DRD is caused by the mutations in the genes encoding the enzymes involved in the dopamine and tetrahydrobiopterin (BH4) biosynthesis, including the GTP cyclohydrolase 1 (GCH1) gene and the tyrosine hydroxylase (TH) gene."
Directly supports impaired dopamine / tetrahydrobiopterin biosynthesis (via GCH1 and TH) as the unifying mechanism of dopa-responsive dystonia.
PMID:34834538 SUPPORT Other
"Dopa-responsive dystonia (DRD) is a rare movement disorder associated with defective dopamine synthesis."
Expert-review framing of DRD as a movement disorder caused by defective dopamine synthesis.
BH4 Cofactor Limitation
GCH1-associated autosomal dominant DRD reduces tetrahydrobiopterin biosynthesis, limiting cofactor availability for tyrosine hydroxylase (and other aromatic-amino-acid hydroxylases) and feeding the shared `Striatal Dopamine Biosynthesis Impairment` endpoint. This node is intentionally absent from the TH-deficient AR arm, where BH4 biosynthesis is intact and the defect is at tyrosine hydroxylase itself.
GCH1 link
tetrahydrobiopterin biosynthetic process link ↓ DECREASED
GTP cyclohydrolase I activity link ↓ DECREASED
Downstream
Striatal Dopamine Biosynthesis Impairment Limiting BH4 cofactor availability impairs aromatic amino-acid hydroxylation and lowers downstream dopamine synthesis.
Transient Hyperphenylalaninemia BH4 cofactor limitation can also impair phenylalanine handling, producing the transient hyperphenylalaninemia recorded for the GTPCH1-deficient branch.
Show evidence (2 references)
DOI:10.1002/mdc3.14157 SUPPORT Human Clinical
"The GCH1 gene encodes the enzyme guanosine triphosphate cyclohydrolase I (GTPCH), which catalyzes the rate‐limiting step in the biosynthesis of tetrahydrobiopterin (BH4), a critical cofactor in the production of monoamine neurotransmitters."
Human GCH1 deficiency review supports BH4 cofactor limitation from reduced GTPCH activity.
PMID:28087438 SUPPORT Human Clinical
"the GTP cyclohydrolase 1 (GCH1) gene and the tyrosine hydroxylase (TH) gene"
Documents GCH1 (BH4-pathway) and TH (terminal-step) as the two enzymatic loci in DRD, supporting separation of the BH4-limited AD-DRD arm from the TH-deficient AR-DRD arm.
Tyrosine Hydroxylase Catalytic Deficiency
In the TH-deficient recessive arm of DRD, biallelic TH variants directly reduce tyrosine hydroxylase activity, the rate-limiting conversion of L-tyrosine toward L-dopa and catecholamine synthesis. This terminal enzymatic bottleneck feeds the shared striatal dopamine-deficiency endpoint independently of the BH4-biosynthesis branch.
TH link
dopamine biosynthetic process from tyrosine link ↓ DECREASED catecholamine biosynthetic process link ↓ DECREASED
tyrosine 3-monooxygenase activity link ↓ DECREASED
Downstream
Striatal Dopamine Biosynthesis Impairment Reduced TH activity lowers catecholamine and dopamine synthesis, feeding the same central dopamine-deficiency endpoint as the BH4-limited branch.
Show evidence (2 references)
PMID:9703425 SUPPORT Human Clinical
"This report concerns one new mutation in the tyrosine hydroxylase (TH) gene in three patients originating from three unrelated Dutch families with autosomal recessive L-DOPA-responsive dystonia (DRD)."
Human mutation evidence links TH variants to autosomal recessive L-DOPA-responsive dystonia.
PMID:34834538 SUPPORT Other
"TH is a key enzyme that catalyzes the rate-limiting step in catecholamine biosynthesis, and THD patients often present with complex and variable phenotypes, which results in frequent misdiagnosis and lack of appropriate treatment."
Expert review supports TH catalytic deficiency as a catecholamine biosynthesis bottleneck.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for Dopa-Responsive Dystonia Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

6
Nervous System 2
Parkinsonism FREQUENT Parkinsonism (HP:0001300)
Show evidence (1 reference)
PMID:20301681 SUPPORT Other
"This disorder typically presents with gait disturbance caused by foot dystonia, later development of parkinsonism, and diurnal fluctuation of symptoms"
GeneReviews directly supports later development of parkinsonism in DRD.
Gait Disturbance VERY_FREQUENT Gait disturbance (HP:0001288)
Temporal: DIURNAL
Show evidence (1 reference)
PMID:33875303 SUPPORT Human Clinical
"gait disturbance was reported in 92.7% of patients, diurnal fluctuation of symptoms in 91.9%, and RMS in 39%."
Meta-analysis directly supports a high (>90%) prevalence of gait disturbance in early-onset autosomal dominant GCH1-deficient DRD.
Other 4
Limb Dystonia FREQUENT Limb dystonia (HP:0002451)
Temporal: DIURNAL
Show evidence (1 reference)
PMID:20301681 SUPPORT Other
"This disorder typically presents with gait disturbance caused by foot dystonia, later development of parkinsonism, and diurnal fluctuation of symptoms"
GeneReviews directly supports foot (limb) dystonia with diurnal fluctuation of symptoms as the typical presenting feature of DRD.
Focal Dystonia FREQUENT Focal dystonia (HP:0004373)
Show evidence (1 reference)
ORPHA:98808 SUPPORT Other
"HP:0004373 | Focal dystonia | Frequent (79-30%)"
Orphanet lists focal dystonia as frequent in autosomal dominant DRD.
Decreased CSF Homovanillic Acid FREQUENT Decreased CSF homovanillic acid concentration (HP:0003785)
Show evidence (2 references)
ORPHA:98808 SUPPORT Other
"| HP:0003785 | Decreased CSF homovanillic acid concentration | Frequent (79-30%) |"
Orphanet lists decreased CSF HVA as frequent in autosomal dominant DRD.
ORPHA:101150 SUPPORT Other
"| HP:0003785 | Decreased CSF homovanillic acid concentration | Frequent (79-30%) |"
Orphanet lists decreased CSF HVA as frequent in autosomal recessive DRD.
Transient Hyperphenylalaninemia FREQUENT Transient hyperphenylalaninemia (HP:0008297)
Show evidence (1 reference)
ORPHA:98808 SUPPORT Other
"| HP:0008297 | Transient hyperphenylalaninemia | Frequent (79-30%) |"
Orphanet lists transient hyperphenylalaninemia as frequent in autosomal dominant DRD.
💊

Treatments

1
Low-dose Levodopa Therapy
Action: Pharmacotherapy NCIT:C15986
Agent: levodopa ↗
Low-dose levodopa, typically paired with a peripheral aromatic L-amino-acid decarboxylase inhibitor (carbidopa or benserazide), bypasses the dopamine-synthesis bottleneck by supplying a downstream dopamine precursor. The dramatic, sustained motor response — often with complete symptom resolution at modest doses — is the defining therapeutic feature of DRD.
Mechanism Target:
BYPASSES Striatal Dopamine Biosynthesis Impairment — Levodopa supplies a downstream dopamine precursor, bypassing upstream BH4 or TH bottlenecks in dopamine biosynthesis.
Show evidence (2 references)
PMID:20301681 SUPPORT Other
"GTP cyclohydrolase 1-deficient dopa-responsive dystonia (GTPCH1-deficient DRD) is characterized by childhood-onset dystonia and a dramatic and sustained response to low doses of oral administration of levodopa."
GeneReviews supports levodopa response downstream of the dopamine-synthesis bottleneck.
PMID:34054692 SUPPORT Human Clinical
"Most DRD patients showed satisfactory treatment outcomes after long-term levodopa, whereas few patients with TH variants presented motor symptoms, which is considered to be related to dopamine insufficiency."
Human cohort links levodopa outcomes to dopamine insufficiency in DRD.
Target Phenotypes: Limb dystonia ↗ Parkinsonism ↗
Show evidence (1 reference)
PMID:20301681 SUPPORT Other
"GTP cyclohydrolase 1-deficient dopa-responsive dystonia (GTPCH1-deficient DRD) is characterized by childhood-onset dystonia and a dramatic and sustained response to low doses of oral administration of levodopa."
GeneReviews directly supports low-dose levodopa as the defining DRD therapy with dramatic sustained response.
🔬

Biochemical Markers

2
CSF homovanillic acid (DECREASED)
Context: CSF homovanillic acid is a dopamine-metabolite biomarker reporting impaired central dopamine synthesis across DRD subtypes.
Pathograph Readouts
Readout Of Striatal Dopamine Biosynthesis Impairment Negative Diagnostic
Low CSF HVA reports reduced central dopamine synthesis.
Show evidence (2 references)
ORPHA:98808 SUPPORT Other
"| HP:0003785 | Decreased CSF homovanillic acid concentration | Frequent (79-30%) |"
Orphanet lists decreased CSF homovanillic acid as frequent in autosomal dominant DRD.
ORPHA:101150 SUPPORT Other
"| HP:0003785 | Decreased CSF homovanillic acid concentration | Frequent (79-30%) |"
Orphanet lists decreased CSF homovanillic acid as frequent in autosomal recessive DRD.
Blood phenylalanine (INCREASED)
Context: Transient hyperphenylalaninemia is a diagnostic readout of the tetrahydrobiopterin-limited aromatic amino-acid hydroxylation branch in GTPCH1-deficient DRD.
Pathograph Readouts
Readout Of BH4 Cofactor Limitation Positive Diagnostic
Elevated phenylalanine reports impaired BH4-dependent phenylalanine handling.
Show evidence (1 reference)
ORPHA:98808 SUPPORT Other
"| HP:0008297 | Transient hyperphenylalaninemia | Frequent (79-30%) |"
Orphanet lists transient hyperphenylalaninemia as frequent in autosomal dominant DRD.
{ }

Source YAML

click to show 
name: Dopa-Responsive Dystonia
creation_date: '2026-05-12T00:00:00Z'
updated_date: '2026-05-20T17:11:42Z'
description: >-
  Dopa-responsive dystonia (DRD) is a group of rare neurometabolic disorders
  in which inherited defects of dopamine biosynthesis cause childhood-onset
  dystonia that responds dramatically and durably to low-dose levodopa.
  Two genetic forms account for the majority of cases. Autosomal dominant
  DRD is most commonly due to heterozygous pathogenic variants in GCH1
  (Segawa disease / GTPCH1-deficient DRD), with rarer dominant variants
  reported in IMPDH2 and NR4A2; it classically presents as childhood foot
  dystonia with diurnal fluctuation that may evolve into parkinsonism later
  in life. Autosomal recessive DRD is most commonly caused by biallelic TH
  (tyrosine hydroxylase) pathogenic variants, with rarer biallelic TSPOAP1
  variants; its phenotype spans levodopa-responsive childhood dystonia,
  infantile parkinsonism with motor delay, and progressive infantile
  encephalopathy. Subtype-specific molecular detail is curated in the
  existing dismech entries `Autosomal_Dominant_Dopa_Responsive_Dystonia`
  and `Autosomal_Recessive_Dopa_Responsive_Dystonia`.
categories:
- Movement Disorder
- Inborn Error of Metabolism
- Pediatric Neurological Disease
has_subtypes:
- name: AD-DRD
  display_name: Autosomal Dominant Dopa-Responsive Dystonia
  description: >-
    Most commonly due to heterozygous GCH1 pathogenic variants
    (Segawa disease / GTPCH1-deficient DRD); rarer dominant causes
    include IMPDH2 and NR4A2 variants. Curated as
    `Autosomal_Dominant_Dopa_Responsive_Dystonia`.
- name: AR-DRD
  display_name: Autosomal Recessive Dopa-Responsive Dystonia
  description: >-
    Most commonly due to biallelic TH (tyrosine hydroxylase) pathogenic
    variants; rarer biallelic TSPOAP1 variants also occur. Phenotypic
    spectrum from levodopa-responsive childhood dystonia to progressive
    infantile encephalopathy. Curated as
    `Autosomal_Recessive_Dopa_Responsive_Dystonia`.
pathophysiology:
- name: Striatal Dopamine Biosynthesis Impairment
  description: >-
    The unifying mechanism across DRD subtypes is reduced dopamine
    biosynthesis in nigrostriatal dopaminergic neurons, either via
    tetrahydrobiopterin-cofactor limitation (classically GCH1; see the
    `BH4 Cofactor Limitation` subtype-specific node) or via direct loss
    of tyrosine-hydroxylase activity (TH). The reversible neurotransmitter
    deficit at this shared endpoint accounts for the dramatic sustained
    response to low-dose levodopa that defines the disease group.
  cell_types:
  - preferred_term: dopaminergic neuron
    term:
      id: CL:0000700
      label: dopaminergic neuron
  biological_processes:
  - preferred_term: dopamine biosynthetic process
    modifier: DECREASED
    term:
      id: GO:0042416
      label: dopamine biosynthetic process
  - preferred_term: dopamine biosynthetic process from tyrosine
    modifier: DECREASED
    term:
      id: GO:0006585
      label: dopamine biosynthetic process from tyrosine
  - preferred_term: catecholamine biosynthetic process
    modifier: DECREASED
    term:
      id: GO:0042423
      label: catecholamine biosynthetic process
  chemical_entities:
  - preferred_term: dopamine
    term:
      id: CHEBI:18243
      label: dopamine
    modifier: DECREASED
  - preferred_term: homovanillic acid
    term:
      id: CHEBI:545959
      label: homovanillic acid
    modifier: DECREASED
  downstream:
  - target: Limb Dystonia
    causal_link_type: DIRECT
    description: >-
      Reduced nigrostriatal dopamine synthesis produces the childhood foot and
      limb dystonia that defines the DRD motor presentation.
    evidence:
    - reference: PMID:34834538
      reference_title: "Personalized Medicine to Improve Treatment of Dopa-Responsive Dystonia-A Focus on Tyrosine Hydroxylase Deficiency."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: >-
        Dopa-responsive dystonia (DRD) is a rare movement disorder associated
        with defective dopamine synthesis.
      explanation: Expert review links DRD to defective dopamine synthesis.
    - reference: PMID:20301681
      reference_title: "GTP Cyclohydrolase 1-Deficient Dopa-Responsive Dystonia."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: >-
        This disorder typically presents with gait disturbance caused by foot
        dystonia, later development of parkinsonism, and diurnal fluctuation of
        symptoms
      explanation: GeneReviews supports foot dystonia as the typical DRD motor presentation.
  - target: Focal Dystonia
    causal_link_type: DIRECT
    description: >-
      The same central dopamine-synthesis deficit can present as focal dystonia,
      especially in the classic autosomal dominant subtype.
    evidence:
    - reference: PMID:34834538
      reference_title: "Personalized Medicine to Improve Treatment of Dopa-Responsive Dystonia-A Focus on Tyrosine Hydroxylase Deficiency."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: >-
        Dopa-responsive dystonia (DRD) is a rare movement disorder associated
        with defective dopamine synthesis.
      explanation: Expert review links the DRD movement-disorder spectrum to defective dopamine synthesis.
    - reference: ORPHA:98808
      reference_title: "Autosomal dominant dopa-responsive dystonia (Orphanet)"
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "HP:0004373 | Focal dystonia | Frequent (79-30%)"
      explanation: Orphanet lists focal dystonia as frequent in autosomal dominant DRD.
  - target: Parkinsonism
    causal_link_type: DIRECT
    description: >-
      Dopamine deficiency in motor circuits explains parkinsonian features in
      older classic DRD and in severe TH-deficient disease.
    evidence:
    - reference: PMID:20301681
      reference_title: "GTP Cyclohydrolase 1-Deficient Dopa-Responsive Dystonia."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: >-
        This disorder typically presents with gait disturbance caused by foot
        dystonia, later development of parkinsonism, and diurnal fluctuation of
        symptoms
      explanation: GeneReviews supports later parkinsonism in classic DRD.
  - target: Gait Disturbance
    causal_link_type: DIRECT
    description: >-
      Foot and limb dystonia from the dopamine-synthesis deficit produces the
      characteristic childhood gait disturbance.
    evidence:
    - reference: PMID:33875303
      reference_title: "Early-onset autosomal dominant GTP-cyclohydrolase I deficiency: Diagnostic delay and residual motor signs."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        gait disturbance was reported in 92.7% of patients, diurnal fluctuation
        of symptoms in 91.9%, and RMS in 39%.
      explanation: Human meta-analysis supports gait disturbance as very frequent in early-onset AD GCH1 deficiency.
  - target: Decreased CSF Homovanillic Acid
    causal_link_type: DIRECT
    description: >-
      Homovanillic acid is a dopamine metabolite, so impaired central dopamine
      synthesis is reflected by low CSF homovanillic acid.
    evidence:
    - reference: ORPHA:98808
      reference_title: "Autosomal dominant dopa-responsive dystonia (Orphanet)"
      supports: SUPPORT
      evidence_source: OTHER
      snippet: >-
        | HP:0003785 | Decreased CSF homovanillic acid concentration | Frequent
        (79-30%) |
      explanation: Orphanet lists decreased CSF homovanillic acid as frequent in autosomal dominant DRD.
    - reference: ORPHA:101150
      reference_title: "Autosomal recessive dopa-responsive dystonia (Orphanet)"
      supports: SUPPORT
      evidence_source: OTHER
      snippet: >-
        | HP:0003785 | Decreased CSF homovanillic acid concentration | Frequent
        (79-30%) |
      explanation: Orphanet lists decreased CSF homovanillic acid as frequent in autosomal recessive DRD.
  evidence:
  - reference: PMID:28087438
    reference_title: "Dopa-responsive dystonia in Chinese patients: Including a novel heterozygous mutation in the GCH1 gene with an intermediate phenotype and one case of prenatal diagnosis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "DRD is caused by the mutations in the genes encoding the enzymes involved in the dopamine and tetrahydrobiopterin (BH4) biosynthesis, including the GTP cyclohydrolase 1 (GCH1) gene and the tyrosine hydroxylase (TH) gene."
    explanation: Directly supports impaired dopamine / tetrahydrobiopterin biosynthesis (via GCH1 and TH) as the unifying mechanism of dopa-responsive dystonia.
  - reference: PMID:34834538
    reference_title: "Personalized Medicine to Improve Treatment of Dopa-Responsive Dystonia-A Focus on Tyrosine Hydroxylase Deficiency."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Dopa-responsive dystonia (DRD) is a rare movement disorder associated with defective dopamine synthesis."
    explanation: Expert-review framing of DRD as a movement disorder caused by defective dopamine synthesis.
- name: BH4 Cofactor Limitation
  description: >-
    GCH1-associated autosomal dominant DRD reduces tetrahydrobiopterin
    biosynthesis, limiting cofactor availability for tyrosine hydroxylase (and
    other aromatic-amino-acid hydroxylases) and feeding the shared `Striatal
    Dopamine Biosynthesis Impairment` endpoint. This node is intentionally
    absent from the TH-deficient AR arm, where BH4 biosynthesis is intact and
    the defect is at tyrosine hydroxylase itself.
  genes:
  - preferred_term: GCH1
    term:
      id: hgnc:4193
      label: GCH1
  biological_processes:
  - preferred_term: tetrahydrobiopterin biosynthetic process
    modifier: DECREASED
    term:
      id: GO:0006729
      label: tetrahydrobiopterin biosynthetic process
  molecular_functions:
  - preferred_term: GTP cyclohydrolase I activity
    modifier: DECREASED
    term:
      id: GO:0003934
      label: GTP cyclohydrolase I activity
  chemical_entities:
  - preferred_term: tetrahydrobiopterin
    term:
      id: CHEBI:15372
      label: 5,6,7,8-tetrahydrobiopterin
    modifier: DECREASED
  - preferred_term: L-phenylalanine
    term:
      id: CHEBI:58095
      label: L-phenylalanine zwitterion
    modifier: INCREASED
  downstream:
  - target: Striatal Dopamine Biosynthesis Impairment
    causal_link_type: DIRECT
    description: >-
      Limiting BH4 cofactor availability impairs aromatic amino-acid
      hydroxylation and lowers downstream dopamine synthesis.
    evidence:
    - reference: DOI:10.1002/mdc3.14157
      reference_title: "Autosomal Recessive Guanosine Triphosphate Cyclohydrolase I Deficiency: Redefining the Phenotypic Spectrum and Outcomes"
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        The GCH1 gene encodes the enzyme guanosine triphosphate cyclohydrolase
        I (GTPCH), which catalyzes the rate‐limiting step in the biosynthesis
        of tetrahydrobiopterin (BH4), a critical cofactor in the production of
        monoamine neurotransmitters.
      explanation: Human GCH1 deficiency review links GTPCH activity to BH4 biosynthesis and monoamine neurotransmitter production.
  - target: Transient Hyperphenylalaninemia
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - BH4 limitation impairs phenylalanine hydroxylase cofactor support, producing transient phenylalanine elevation.
    description: >-
      BH4 cofactor limitation can also impair phenylalanine handling, producing
      the transient hyperphenylalaninemia recorded for the GTPCH1-deficient
      branch.
    evidence:
    - reference: ORPHA:98808
      reference_title: "Autosomal dominant dopa-responsive dystonia (Orphanet)"
      supports: SUPPORT
      evidence_source: OTHER
      snippet: >-
        | HP:0008297 | Transient hyperphenylalaninemia | Frequent (79-30%) |
      explanation: Orphanet lists transient hyperphenylalaninemia in the autosomal dominant DRD record.
  evidence:
  - reference: DOI:10.1002/mdc3.14157
    reference_title: "Autosomal Recessive Guanosine Triphosphate Cyclohydrolase I Deficiency: Redefining the Phenotypic Spectrum and Outcomes"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The GCH1 gene encodes the enzyme guanosine triphosphate cyclohydrolase I
      (GTPCH), which catalyzes the rate‐limiting step in the biosynthesis of
      tetrahydrobiopterin (BH4), a critical cofactor in the production of
      monoamine neurotransmitters.
    explanation: Human GCH1 deficiency review supports BH4 cofactor limitation from reduced GTPCH activity.
  - reference: PMID:28087438
    reference_title: "Dopa-responsive dystonia in Chinese patients: Including a novel heterozygous mutation in the GCH1 gene with an intermediate phenotype and one case of prenatal diagnosis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "the GTP cyclohydrolase 1 (GCH1) gene and the tyrosine hydroxylase (TH) gene"
    explanation: Documents GCH1 (BH4-pathway) and TH (terminal-step) as the two enzymatic loci in DRD, supporting separation of the BH4-limited AD-DRD arm from the TH-deficient AR-DRD arm.
- name: Tyrosine Hydroxylase Catalytic Deficiency
  description: >-
    In the TH-deficient recessive arm of DRD, biallelic TH variants directly
    reduce tyrosine hydroxylase activity, the rate-limiting conversion of
    L-tyrosine toward L-dopa and catecholamine synthesis. This terminal
    enzymatic bottleneck feeds the shared striatal dopamine-deficiency endpoint
    independently of the BH4-biosynthesis branch.
  genes:
  - preferred_term: TH
    term:
      id: hgnc:11782
      label: TH
  molecular_functions:
  - preferred_term: tyrosine 3-monooxygenase activity
    modifier: DECREASED
    term:
      id: GO:0004511
      label: tyrosine 3-monooxygenase activity
  biological_processes:
  - preferred_term: dopamine biosynthetic process from tyrosine
    modifier: DECREASED
    term:
      id: GO:0006585
      label: dopamine biosynthetic process from tyrosine
  - preferred_term: catecholamine biosynthetic process
    modifier: DECREASED
    term:
      id: GO:0042423
      label: catecholamine biosynthetic process
  chemical_entities:
  - preferred_term: L-tyrosine
    term:
      id: CHEBI:58315
      label: L-tyrosine zwitterion
  - preferred_term: L-dopa
    term:
      id: CHEBI:15765
      label: L-dopa
    modifier: DECREASED
  - preferred_term: dopamine
    term:
      id: CHEBI:18243
      label: dopamine
    modifier: DECREASED
  downstream:
  - target: Striatal Dopamine Biosynthesis Impairment
    causal_link_type: DIRECT
    description: >-
      Reduced TH activity lowers catecholamine and dopamine synthesis, feeding
      the same central dopamine-deficiency endpoint as the BH4-limited branch.
    evidence:
    - reference: PMID:34834538
      reference_title: "Personalized Medicine to Improve Treatment of Dopa-Responsive Dystonia-A Focus on Tyrosine Hydroxylase Deficiency."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: >-
        TH is a key enzyme that catalyzes the rate-limiting step in
        catecholamine biosynthesis, and THD patients often present with complex
        and variable phenotypes, which results in frequent misdiagnosis and lack
        of appropriate treatment.
      explanation: Expert review supports TH as the rate-limiting catecholamine enzyme and links THD to DRD phenotypes.
  evidence:
  - reference: PMID:9703425
    reference_title: "A common point mutation in the tyrosine hydroxylase gene in autosomal recessive L-DOPA-responsive dystonia in the Dutch population."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      This report concerns one new mutation in the tyrosine hydroxylase (TH)
      gene in three patients originating from three unrelated Dutch families
      with autosomal recessive L-DOPA-responsive dystonia (DRD).
    explanation: Human mutation evidence links TH variants to autosomal recessive L-DOPA-responsive dystonia.
  - reference: PMID:34834538
    reference_title: "Personalized Medicine to Improve Treatment of Dopa-Responsive Dystonia-A Focus on Tyrosine Hydroxylase Deficiency."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      TH is a key enzyme that catalyzes the rate-limiting step in catecholamine
      biosynthesis, and THD patients often present with complex and variable
      phenotypes, which results in frequent misdiagnosis and lack of appropriate
      treatment.
    explanation: Expert review supports TH catalytic deficiency as a catecholamine biosynthesis bottleneck.
phenotypes:
- category: Neurologic
  name: Limb Dystonia
  frequency: FREQUENT
  description: >-
    Limb dystonia — most often foot dystonia presenting as childhood gait
    disturbance — is a hallmark cross-subtype feature.
  phenotype_term:
    preferred_term: Limb dystonia
    term:
      id: HP:0002451
      label: Limb dystonia
    temporality: DIURNAL
  evidence:
  - reference: PMID:20301681
    reference_title: "GTP Cyclohydrolase 1-Deficient Dopa-Responsive Dystonia."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "This disorder typically presents with gait disturbance caused by foot dystonia, later development of parkinsonism, and diurnal fluctuation of symptoms"
    explanation: GeneReviews directly supports foot (limb) dystonia with diurnal fluctuation of symptoms as the typical presenting feature of DRD.
- category: Neurologic
  name: Focal Dystonia
  frequency: FREQUENT
  description: >-
    Focal dystonia (in a single body region) is a common DRD pattern,
    particularly early in the course before generalisation.
  phenotype_term:
    preferred_term: Focal dystonia
    term:
      id: HP:0004373
      label: Focal dystonia
  evidence:
  - reference: ORPHA:98808
    reference_title: "Autosomal dominant dopa-responsive dystonia (Orphanet)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0004373 | Focal dystonia | Frequent (79-30%)"
    explanation: Orphanet lists focal dystonia as frequent in autosomal dominant DRD.
- category: Neurologic
  name: Parkinsonism
  frequency: FREQUENT
  description: >-
    Parkinsonism (bradykinesia, rigidity, tremor) appears later in life in
    autosomal dominant DRD and can present in infancy in severe TH
    deficiency.
  phenotype_term:
    preferred_term: Parkinsonism
    term:
      id: HP:0001300
      label: Parkinsonism
  evidence:
  - reference: PMID:20301681
    reference_title: "GTP Cyclohydrolase 1-Deficient Dopa-Responsive Dystonia."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "This disorder typically presents with gait disturbance caused by foot dystonia, later development of parkinsonism, and diurnal fluctuation of symptoms"
    explanation: GeneReviews directly supports later development of parkinsonism in DRD.
- category: Neurologic
  name: Gait Disturbance
  frequency: VERY_FREQUENT
  description: >-
    Gait disturbance from foot dystonia is the typical presenting symptom
    in childhood-onset DRD and frequent in autosomal dominant GCH1
    deficiency at presentation.
  phenotype_term:
    preferred_term: Gait disturbance
    term:
      id: HP:0001288
      label: Gait disturbance
    temporality: DIURNAL
  evidence:
  - reference: PMID:33875303
    reference_title: "Early-onset autosomal dominant GTP-cyclohydrolase I deficiency: Diagnostic delay and residual motor signs."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "gait disturbance was reported in 92.7% of patients, diurnal fluctuation of symptoms in 91.9%, and RMS in 39%."
    explanation: Meta-analysis directly supports a high (>90%) prevalence of gait disturbance in early-onset autosomal dominant GCH1-deficient DRD.
- category: Biochemical
  name: Decreased CSF Homovanillic Acid
  frequency: FREQUENT
  description: >-
    Low CSF homovanillic acid is a dopamine-metabolite readout of impaired
    central dopamine synthesis and is listed as frequent in both classic
    autosomal dominant and TH-deficient autosomal recessive DRD records.
  phenotype_term:
    preferred_term: Decreased CSF homovanillic acid concentration
    term:
      id: HP:0003785
      label: Decreased CSF homovanillic acid concentration
  evidence:
  - reference: ORPHA:98808
    reference_title: "Autosomal dominant dopa-responsive dystonia (Orphanet)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      | HP:0003785 | Decreased CSF homovanillic acid concentration | Frequent
      (79-30%) |
    explanation: Orphanet lists decreased CSF HVA as frequent in autosomal dominant DRD.
  - reference: ORPHA:101150
    reference_title: "Autosomal recessive dopa-responsive dystonia (Orphanet)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      | HP:0003785 | Decreased CSF homovanillic acid concentration | Frequent
      (79-30%) |
    explanation: Orphanet lists decreased CSF HVA as frequent in autosomal recessive DRD.
- category: Metabolic
  name: Transient Hyperphenylalaninemia
  subtype: AD-DRD
  frequency: FREQUENT
  description: >-
    Transient hyperphenylalaninemia is a BH4-branch metabolic phenotype in the
    autosomal dominant GTPCH1-deficient record, reflecting impaired
    BH4-dependent aromatic amino-acid hydroxylation.
  phenotype_term:
    preferred_term: Transient hyperphenylalaninemia
    term:
      id: HP:0008297
      label: Transient hyperphenylalaninemia
  evidence:
  - reference: ORPHA:98808
    reference_title: "Autosomal dominant dopa-responsive dystonia (Orphanet)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      | HP:0008297 | Transient hyperphenylalaninemia | Frequent (79-30%) |
    explanation: Orphanet lists transient hyperphenylalaninemia as frequent in autosomal dominant DRD.
biochemical:
- name: CSF homovanillic acid
  presence: DECREASED
  context: >-
    CSF homovanillic acid is a dopamine-metabolite biomarker reporting impaired
    central dopamine synthesis across DRD subtypes.
  biomarker_term:
    preferred_term: CSF homovanillic acid
    term:
      id: CHEBI:545959
      label: homovanillic acid
  readouts:
  - target: Striatal Dopamine Biosynthesis Impairment
    relationship: READOUT_OF
    direction: NEGATIVE
    endpoint_context: DIAGNOSTIC
    interpretation: Low CSF HVA reports reduced central dopamine synthesis.
  evidence:
  - reference: ORPHA:98808
    reference_title: "Autosomal dominant dopa-responsive dystonia (Orphanet)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      | HP:0003785 | Decreased CSF homovanillic acid concentration | Frequent
      (79-30%) |
    explanation: Orphanet lists decreased CSF homovanillic acid as frequent in autosomal dominant DRD.
  - reference: ORPHA:101150
    reference_title: "Autosomal recessive dopa-responsive dystonia (Orphanet)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      | HP:0003785 | Decreased CSF homovanillic acid concentration | Frequent
      (79-30%) |
    explanation: Orphanet lists decreased CSF homovanillic acid as frequent in autosomal recessive DRD.
- name: Blood phenylalanine
  presence: INCREASED
  context: >-
    Transient hyperphenylalaninemia is a diagnostic readout of the
    tetrahydrobiopterin-limited aromatic amino-acid hydroxylation branch in
    GTPCH1-deficient DRD.
  biomarker_term:
    preferred_term: L-phenylalanine
    term:
      id: CHEBI:58095
      label: L-phenylalanine zwitterion
  readouts:
  - target: BH4 Cofactor Limitation
    relationship: READOUT_OF
    direction: POSITIVE
    endpoint_context: DIAGNOSTIC
    interpretation: Elevated phenylalanine reports impaired BH4-dependent phenylalanine handling.
  evidence:
  - reference: ORPHA:98808
    reference_title: "Autosomal dominant dopa-responsive dystonia (Orphanet)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      | HP:0008297 | Transient hyperphenylalaninemia | Frequent (79-30%) |
    explanation: Orphanet lists transient hyperphenylalaninemia as frequent in autosomal dominant DRD.
diagnosis:
- name: Molecular genetic testing
  presence: Positive
  description: >-
    Root-level DRD diagnosis is resolved by subtype-specific molecular testing,
    especially heterozygous GCH1 pathogenic variants in classic autosomal
    dominant DRD and biallelic TH pathogenic variants in TH deficiency.
  evidence:
  - reference: PMID:20301681
    reference_title: "GTP Cyclohydrolase 1-Deficient Dopa-Responsive Dystonia."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      The diagnosis of GTPCH1-deficient DRD is established in a proband by
      identification of a heterozygous pathogenic variant in GCH1 by molecular
      genetic testing.
    explanation: GeneReviews supports GCH1 molecular diagnosis for classic autosomal dominant DRD.
  - reference: PMID:20301610
    reference_title: "Tyrosine Hydroxylase Deficiency."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      The diagnosis of TH deficiency is established in a proband by
      identification of biallelic pathogenic variants in TH by molecular genetic
      testing.
    explanation: GeneReviews supports TH molecular diagnosis for the autosomal recessive DRD subtype.
- name: CSF neurotransmitter metabolite testing
  presence: Decreased CSF homovanillic acid
  description: >-
    Low CSF homovanillic acid supports a central dopamine-synthesis defect and
    can help distinguish DRD subtype mechanisms when genetic testing is
    unrevealing or phenotype severity is atypical.
  evidence:
  - reference: ORPHA:98808
    reference_title: "Autosomal dominant dopa-responsive dystonia (Orphanet)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      | HP:0003785 | Decreased CSF homovanillic acid concentration | Frequent
      (79-30%) |
    explanation: Orphanet supports decreased CSF HVA as a biochemical diagnostic clue in autosomal dominant DRD.
  - reference: ORPHA:101150
    reference_title: "Autosomal recessive dopa-responsive dystonia (Orphanet)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      | HP:0003785 | Decreased CSF homovanillic acid concentration | Frequent
      (79-30%) |
    explanation: Orphanet supports decreased CSF HVA as a biochemical diagnostic clue in autosomal recessive DRD.
- name: Levodopa responsiveness
  presence: Positive
  description: >-
    Dramatic or marked response to levodopa is a defining clinical clue for DRD,
    although response completeness varies across the TH-deficient severity
    spectrum.
  evidence:
  - reference: PMID:20301681
    reference_title: "GTP Cyclohydrolase 1-Deficient Dopa-Responsive Dystonia."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      GTP cyclohydrolase 1-deficient dopa-responsive dystonia
      (GTPCH1-deficient DRD) is characterized by childhood-onset dystonia and a
      dramatic and sustained response to low doses of oral administration of
      levodopa.
    explanation: GeneReviews supports dramatic levodopa responsiveness as a core feature of classic DRD.
  - reference: PMID:20301610
    reference_title: "Tyrosine Hydroxylase Deficiency."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      All individuals with TH-deficient DRD demonstrate complete responsiveness
      of symptoms to levodopa (with a decarboxylase inhibitor).
    explanation: GeneReviews supports levodopa responsiveness in TH-deficient DRD.
treatments:
- name: Low-dose Levodopa Therapy
  description: >-
    Low-dose levodopa, typically paired with a peripheral aromatic
    L-amino-acid decarboxylase inhibitor (carbidopa or benserazide),
    bypasses the dopamine-synthesis bottleneck by supplying a downstream
    dopamine precursor. The dramatic, sustained motor response — often
    with complete symptom resolution at modest doses — is the defining
    therapeutic feature of DRD.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: levodopa
      term:
        id: CHEBI:15765
        label: L-dopa
  target_phenotypes:
  - preferred_term: Limb dystonia
    term:
      id: HP:0002451
      label: Limb dystonia
  - preferred_term: Parkinsonism
    term:
      id: HP:0001300
      label: Parkinsonism
  target_mechanisms:
  - target: Striatal Dopamine Biosynthesis Impairment
    treatment_effect: BYPASSES
    description: >-
      Levodopa supplies a downstream dopamine precursor, bypassing upstream BH4
      or TH bottlenecks in dopamine biosynthesis.
    evidence:
    - reference: PMID:20301681
      reference_title: "GTP Cyclohydrolase 1-Deficient Dopa-Responsive Dystonia."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: >-
        GTP cyclohydrolase 1-deficient dopa-responsive dystonia
        (GTPCH1-deficient DRD) is characterized by childhood-onset dystonia and
        a dramatic and sustained response to low doses of oral administration of
        levodopa.
      explanation: GeneReviews supports levodopa response downstream of the dopamine-synthesis bottleneck.
    - reference: PMID:34054692
      reference_title: "Identification of TH Variants in Chinese Dopa-Responsive Dystonia Patients and Long-Term Outcomes."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Most DRD patients showed satisfactory treatment outcomes after long-term
        levodopa, whereas few patients with TH variants presented motor
        symptoms, which is considered to be related to dopamine insufficiency.
      explanation: Human cohort links levodopa outcomes to dopamine insufficiency in DRD.
  evidence:
  - reference: PMID:20301681
    reference_title: "GTP Cyclohydrolase 1-Deficient Dopa-Responsive Dystonia."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "GTP cyclohydrolase 1-deficient dopa-responsive dystonia (GTPCH1-deficient DRD) is characterized by childhood-onset dystonia and a dramatic and sustained response to low doses of oral administration of levodopa."
    explanation: GeneReviews directly supports low-dose levodopa as the defining DRD therapy with dramatic sustained response.
notes: >-
  This entry is a root-level dismech record organising the autosomal
  dominant and autosomal recessive forms of dopa-responsive dystonia.
  Subtype-specific pathophysiology (GCH1 / IMPDH2 / NR4A2 in AD-DRD; TH /
  TSPOAP1 in AR-DRD), the spectrum from infantile encephalopathy to adult
  parkinsonism in TH deficiency, and subtype-specific phenotypes such as
  oculogyric crises are curated in the existing subtype files
  (`Autosomal_Dominant_Dopa_Responsive_Dystonia`,
  `Autosomal_Recessive_Dopa_Responsive_Dystonia`).
references:
- reference: PMID:20301681
  title: GTP Cyclohydrolase 1-Deficient Dopa-Responsive Dystonia
  tags:
  - GeneReviews
- reference: PMID:20301610
  title: Tyrosine Hydroxylase Deficiency
  tags:
  - GeneReviews
disease_term:
  preferred_term: dopa-responsive dystonia
  term:
    id: MONDO:0016812
    label: dopa-responsive dystonia
📚

References & Deep Research

References

2
PMID:20301681
GTP Cyclohydrolase 1-Deficient Dopa-Responsive Dystonia
No top-level findings curated for this source.
PMID:20301610
Tyrosine Hydroxylase Deficiency
No top-level findings curated for this source.

Deep Research

1
Dopa-Responsive Dystonia Deep Research Fallback ▸

Dopa-Responsive Dystonia Deep Research Fallback

Provider Attempts

No deep-research provider was invoked for this root-level entry. The two autosomal-form subtype entries (Autosomal_Dominant_Dopa_Responsive_Dystonia, Autosomal_Recessive_Dopa_Responsive_Dystonia) already have their own -deep-research-fallback.md artifacts from prior curation runs (falcon and openai providers were attempted there and terminated on silence; curation proceeded from Orphanet structured records plus a bounded set of fetched PubMed/DOI references).

This root-level entry was curated directly from the verified literature already cached in references_cache/ and shared by both subtype files; no provider was re-run because the root scope only synthesises cross-subtype features that were already established at the subtype level.

Integrated Literature Synthesis

Dopa-responsive dystonia is a group of rare neurometabolic disorders in which inherited defects of dopamine biosynthesis cause childhood-onset dystonia with a dramatic, sustained response to low-dose levodopa. The group is mechanistically heterogeneous but converges on a shared striatal dopamine-biosynthesis impairment in nigrostriatal dopaminergic neurons (CL:0000700, GO:0042416).

Autosomal dominant DRD — most commonly caused by heterozygous GCH1 pathogenic variants (GTPCH1-deficient DRD / Segawa disease). Rarer dominant causes include IMPDH2 and NR4A2 variants. The upstream defect in the GCH1/IMPDH2 arm is reduced tetrahydrobiopterin biosynthesis (GO:0006729, modelled here in a separate BH4 Cofactor Limitation pathophysiology node), limiting cofactor availability for tyrosine hydroxylase. NR4A2 haploinsufficiency produces dopaminergic denervation on DAT imaging without a clear BH4 step. PMID:20301681, PMID:8852666, PMID:33875303 and ORPHA:98808 are the principal supporting references; all live in references_cache/.

Autosomal recessive DRD — most commonly caused by biallelic TH (tyrosine hydroxylase) variants. The phenotypic spectrum spans levodopa-responsive childhood dystonia, infantile parkinsonism with motor delay, and progressive infantile encephalopathy. Rarer biallelic TSPOAP1 variants also occur. In TH-deficient DRD the BH4 step is intact — the defect is at tyrosine hydroxylase itself — which is why this root entry isolates the BH4 limitation in its own pathophysiology node rather than placing it on the unifying dopamine-biosynthesis endpoint (see PR review on #2654). PMID:34834538, ORPHA:101150 supporting.

Shared clinical syndrome. Limb dystonia (HP:0002451, frequently foot-onset, with diurnal fluctuation captured via temporality: DIURNAL), focal dystonia (HP:0004373), parkinsonism (HP:0001300), and gait disturbance (HP:0001288, also diurnal) are shared across genotypes. PMID:33875303 reports gait disturbance in 92.7 % and diurnal fluctuation in 91.9 % of early-onset autosomal- dominant GCH1-deficient DRD patients.

Shared therapy. Low-dose levodopa (CHEBI:15765) with a peripheral aromatic L-amino-acid decarboxylase inhibitor (carbidopa or benserazide) bypasses the dopamine-synthesis bottleneck and is the defining therapeutic feature of the disease group. PMID:20301681 ("characterized by ... a dramatic and sustained response to low doses of oral administration of levodopa") is the canonical evidence.

Out of scope for the root entry

  • Subtype-specific molecular pathways (GCH1, IMPDH2, NR4A2, TH, TSPOAP1) — covered in the existing subtype dismech files.
  • Severe AR-DRD phenotypes such as oculogyric crises, hypotonia, and the encephalopathic end of the TH-deficiency spectrum — these belong in Autosomal_Recessive_Dopa_Responsive_Dystonia.
  • Differential diagnosis with juvenile parkinsonism, secondary dystonia syndromes, and BH4-deficiency metabolic disorders outside the DRD spectrum.